The occurrence of grade 4 adverse events and survival outcomes in patients with nonsquamous non-small cell lung cancer receiving bevacizumab with chemotherapy in the phase III PointBreak and AVAiL studies.
Liza Cosca Villaruz
No relevant relationships to disclose
Mark A. Socinski
Honoraria - Lilly
Research Funding - Lilly
Jyoti D. Patel
No relevant relationships to disclose
Larry Leon
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Sebastien Hazard
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Martin Reck
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech